Menopausal hormone therapy not associated with mortality or deaths from CVD

September 12, 2017

The Women's Health Initiative (WHI) hormone therapy trials tested the most common formulations of hormone therapy - estrogen and progestin, and estrogen alone - to assess the benefits and risks of menopausal hormone therapy taken for chronic disease prevention, by predominantly healthy postmenopausal women. Health outcomes have been previously reported but the earlier reports did not focus specifically on all-cause mortality and cause-specific mortality. A new study led by investigators at Brigham and Women's Hospital published in JAMA on September 12, 2017, is the first to examine the long-term rates of death from all-causes, and the rates of death from specific causes, including cardiovascular disease, cancer and other major illnesses over a follow-up of 18 years among 27,347 women from the two WHI hormone therapy trials. In the overall study of women ages 50-79, researchers found no increase or decrease in total mortality or deaths from cardiovascular disease, cancer or other major illnesses in the randomized hormone therapy trials.

"All-cause provides a critically important summary measure for an intervention such as therapy that has a complex matrix of benefits and risks," stated JoAnn Manson, MD, DrPH, lead author and Chief, Division of Preventive Medicine at BWH. "Mortality rates are the ultimate 'bottom line' when assessing the net effect of a medication on serious and life-threatening health outcomes."

Hormone therapy is known to be effective in reducing hot flashes and menopausal symptoms, and decreasing the risk of hip and other fractures, but it has been also linked to risks including venous blood clots, stroke, and certain cancers. "In this new analysis, we found that there was no association between hormone therapy and all-cause mortality during either the treatment period or the long-term follow-up of these trials," Manson said.

Researchers used data from the two trials which included postmenopausal women with an average age of 63 at enrollment - and explored the effect of treatment over a five to seven-year period, and 18 years of cumulative follow-up, and then defined the impact of hormone therapy on mortality rates by age group. During the follow-up, 7,489 deaths occurred, more than twice as many deaths as were included in earlier reports that had shorter follow-up periods. When examined by ten-year age groups, mortality outcomes were more favorable among younger women who received hormone therapy when compared to older women who also received the therapy. During the five to seven years of treatment, the death rates in the women aged 50-59 tended to be approximately 30 percent lower among women who received hormone therapy when compared to women of the same age who received placebo. However, among women who initiated hormone therapy in their 60s and 70s, no effect on rate was observed. After 18 years, which included 10-12 years of follow-up after stopping hormone therapy, the differences by age group diminished and were no longer statistically significant. Over this extended follow-up period, overall and deaths from and cancer were neither increased nor decreased among women who received hormone therapy. The team also found that deaths from Alzheimer's Disease and other forms of dementia were significantly lower with estrogen-alone than with placebo during 18 years of follow-up, but use of estrogen plus progestin was not associated with dementia mortality.

"We observed a trend toward reduced mortality in younger women (age 50-59) who received hormone therapy, and neutral effects in older women (in their 60s and 70s) who received hormone therapy. These findings provide support for clinical guidelines endorsing the use of hormone therapy for recently menopausal women to manage bothersome hot flashes and other menopausal symptoms. However, the findings do not provide support for the use of hormone therapy for the prevention of cardiovascular disease or other chronic diseases," Manson said. "In clinical decision making, these considerations must be weighed against the impact of untreated that experience, including impaired quality of life, disrupted sleep, reduced work productivity and increased health care expenditures."

The WHI hormone therapy trials addressed the benefits and risks of the most common formulations of hormone used at the start of the study. It is important to note that in current clinical practice, lower doses, different formulations and novel administration methods (such as skin patches, gels, or sprays) of are available and increasingly common. Additional research on the long-term benefits and risks of these newer treatments is needed, the researchers say.

Explore further: Additional studies needed to evaluate CVD risks of hormone therapy for transgender patients

More information: JAMA (2017). DOI: 10.1001/jama.2017.11217

Related Stories

Additional studies needed to evaluate CVD risks of hormone therapy for transgender patients

July 24, 2017
A new narrative review authored by Carl Streed Jr., MD, at Brigham and Women's Hospital, published in the Annals of Internal Medicine, discusses how more research is needed to better understand cardiovascular disease (CVD) ...

Study finds hormone therapy improves sleep quality for recently menopausal women

August 29, 2017
For many women, the side effects of menopause don't call it a day when they do.

Hormone therapy not advised for preventing disease after menopause

May 17, 2017
(HealthDay)—Using hormone therapy to prevent chronic health issues, such as heart disease and bone loss, in postmenopausal women may do more harm than good, the U.S. Preventive Services Task Force (USPSTF) says.

NAMS 2017 position statement updates guidelines for hormone therapy use

June 20, 2017
A new position statement on the use of hormone therapy (HT) for menopausal and postmenopausal women from The North American Menopause Society (NAMS) has been published online today in the Society's journal, Menopause. "The ...

Postmenopausal hormone therapy associated with higher risk of hearing loss

May 10, 2017
Hearing loss afflicts approximately 48 million Americans and the number is expected to increase as the population ages. Some previous studies suggested that menopause may increase the risk for hearing loss, presumably due ...

Recommended for you

Breathing dirty air may harm kidneys, study finds

September 21, 2017
Outdoor air pollution has long been linked to major health conditions such as heart disease, stroke, cancer, asthma and chronic obstructive pulmonary disease. A new study now adds kidney disease to the list, according to ...

Excess dietary manganese promotes staph heart infection

September 21, 2017
Too much dietary manganese—an essential trace mineral found in leafy green vegetables, fruits and nuts—promotes infection of the heart by the bacterium Staphylococcus aureus ("staph").

Being active saves lives whether a gym workout, walking to work or washing the floor

September 21, 2017
Physical activity of any kind can prevent heart disease and death, says a large international study involving more than 130,000 people from 17 countries published this week in The Lancet.

Frequent blood donations safe for some, but not all

September 21, 2017
(HealthDay)—Some people may safely donate blood as often as every eight weeks—but that may not be a healthy choice for all, a new study suggests.

Higher manganese levels in children correlate with lower IQ scores, study finds

September 21, 2017
A study led by environmental health researchers at the University of Cincinnati (UC) College of Medicine finds that children in East Liverpool, Ohio with higher levels of Manganese (Mn) had lower IQ scores. The research appears ...

Higher levels of fluoride in pregnant woman linked to lower intelligence in their children

September 20, 2017
Fluoride in the urine of pregnant women shows a correlation with lower measures of intelligence in their children, according to University of Toronto researchers who conducted the first study of its kind and size to examine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.